美国风湿病学会关于抗疟药心脏毒性的白皮书
羟氯喹(HCQ)和氯喹(CQ)广泛用于系统性红斑狼疮、类风湿关节炎及皮肤型狼疮等。该白皮书由风湿病学、心脏病学和皮肤病学专家组成的工作组通过非系统性文献综述和共识形成,总结HCQ/CQ心脏毒性,指出其可致QTc延长,长期使用可能致心肌病,需权衡风险获益。
要点
- HCQ/CQ可直接影响心脏复极导致QTc延长,尤其合用其他延长QTc药物时需警惕。
- 长期使用HCQ/CQ可能导致与心律失常和心力衰竭相关的心肌病。
- 用药前及用药过程中均应进行风险获益评估,心脏毒性虽罕见但可致命。
核心结论
- HCQ和CQ是治疗风湿性和皮肤疾病的重要药物,但可通过直接影响心脏复极导致QTc延长,长期使用可能导致心肌病,心脏毒性虽罕见但可致命。
研究设计与样本
- 由风湿病学、心脏病学和皮肤病学专家组成的工作组进行非系统性文献综述并提供基于共识的专家意见。
主要发现
- 已有报道显示HCQ/CQ使用与心律失常、传导系统异常及心肌病相关。
- 当前数据明确表明HCQ和CQ通过直接影响心脏复极导致QTc延长。
- 长期使用HCQ/CQ可能导致与心律失常和心力衰竭相关的心肌病。
临床怎么用
- 处方医生应认识到HCQ/CQ的QTc延长效应,尤其对同时使用其他延长QTc间期药物的患者。
- 在开始任何药物治疗前应考虑风险获益评估,且初始和持续的风险获益评估对HCQ/CQ处方均重要。
局限性
- 工作组进行的是非系统性文献综述,基于共识的专家意见。
- 需要额外研究以更好理解这些疗法用于风湿性和皮肤疾病时的心血管风险与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hydroxychloroquine (HCQ) and chloroquine (CQ) are well-established medications used in treating systemic lupus erythematosus and rheumatoid arthritis, as well as skin conditions such as cutaneous lupus erythematosus. In rare cases, arrhythmias and conduction system abnormalities, as well as cardiomyopathy, have been reported in association with HCQ/CQ use. Recently, however, the corrected QT interval (QTc)-prolonging potential of these medications, and risk of torsade de pointes (TdP) in particular, have been highlighted in the setting of their experimental use for COVID-19 infection. This report was undertaken to summarize the current understanding of HCQ/CQ cardiac toxicity, describe QTc prolongation and TdP risks, and discuss areas of priority for future research. A working group of experts across rheumatology, cardiology, and dermatology performed a nonsystematic literature review and offered a consensus-based expert opinion. Current data clearly indicate that HCQ and CQ are invaluable medications in the management of rheumatic and dermatologic diseases, but they are associated with QTc prolongation by directly affecting cardiac repolarization. Prescribing clinicians should be cognizant of this small effect, especially in patients taking additional medications that prolong the QTc interval. Long-term use of HCQ/CQ may lead to a cardiomyopathy associated with arrhythmias and heart failure. Risk and benefit assessment should be considered prior to initiation of any medication, and both initial and ongoing risk-benefit assessments are important with regard to prescription of HCQ/CQ. While cardiac toxicity related to HCQ/CQ treatment of rheumatic diseases is rarely reported, it can be fatal. Awareness of the potential adverse cardiac effects of HCQ and CQ can increase the safe use of these medications. There is a clear need for additional research to allow better understanding of the cardiovascular risk and safety profile of these therapies used in the management of rheumatic and cutaneous diseases.
引用
- Desmarais J, Rosenbaum JT, Costenbader KH, et al. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. Arthritis Rheumatol. 2021. PMID: 34697918. doi:10.1002/art.41934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。